Guerbet (GBT) EUR1

Sell:€26.60Buy:€27.85€0.40 (1.46%)

Prices delayed by at least 15 minutes
Sell:€26.60
Buy:€27.85
Change:€0.40 (1.46%)
Deal now
Prices delayed by at least 15 minutes
Sell:€26.60
Buy:€27.85
Change:€0.40 (1.46%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.

Key people

David Hale
Chairman of the Executive Committee, Chief Executive Officer
Jerome Estampes
Chief Financial Officer, Senior Vice President - IT and Business Development and Licensing, Member of the Executive Committee
Charlotte Bamiere
Senior Vice President - Compliance, General Counsel, Member of the Executive Committee
Valerie Brissart
Senior Vice President - Marketing - Diagnostic Imaging, Member of the Executive Committee
Eva Ohlsson
Senior Vice President - Human Resources, Member of the Executive Committee
Christine Allard
Senior Vice President - Public Affairs and Corporate Communications, Member of the Executive Committee
Raoul Bernhardt
Senior Vice President - Industrial Operations, EHS and Procurement, Member of the Executive Committee
Philippe Bourrinet
Senior Vice President - Development, Medical and Regulatory Affairs and Group Responsible Pharmacist, Member of the Executive Committee
Francois Nicolas
Senior Vice President - Research, Development, Innovation and AI, Member of the Executive Committee
Dan Raffi
Senior Vice President - Commercial Operations, Member of the Executive Committee
Hugues Lecat
Independent Chairman of the Board
Carine Dagommer
Director
Marie de La Simone
Director
Mark Fouquet
Director
Eric Guerbet
Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    FR0000032526
  • Market cap
    €347.00m
  • Employees
    2,920
  • Shares in issue
    12.64m
  • Exchange
    Euronext Paris
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.